Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis
Get Alerts EVOK Hot Sheet
Join SI Premium – FREE
SOLANA BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech Analyst at Laidlaw & Company will host a fireside chat on Thursday, April 1, 2021, at 1:00pm ET with Dr. Kostas Sideridis, DO, an early adopter of GIMOTI and co-founder of Long Island Gastro, and Dr. Richard McCallum, MD, Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center El Paso.
Details of the fireside chat are below: | |
Date: | Thursday, April 1, 2021 |
Location: | https://edge.media-server.com/mmc/p/hszv2spz |
Time: | 1:00pm ET |
In addition, investors are encouraged to email [email protected] prior to the event with questions they may have for Dr. Sideridis and Dr. McCallum. During the call, Laidlaw & Company may be asking several submitted questions to Dr. Sideridis and Dr. McCallum.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Investor Contacts:The Ruth GroupChristine Petraglia / James SaliernoTel: 917-633-8980 / 973-255-8361[email protected] / [email protected]
Media Contact:The Ruth GroupAnnika ParrishTel: 720-412-9042[email protected]
Source: Evoke Pharma, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPACEMOBILE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against AST SpaceMobile, Inc. and Encourages Investors to Contact the Firm
- Builders Capital Mortgage Corp. Releases Annual Financial Statements; Reports Strong Results for 2023: Annual Income up 21.6% Year-Over-Year
- Cybeats Announces Filing of MCTO Application
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!